Reading ECG? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ECG free→Reading ECG? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ECG free→NYSEIndustrialsEngineering & ConstructionSnapshot 2026-06-12
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and earnings quality is also neutral. Risk is elevated, and the sector backdrop presents a headwind. Compared with sector peers, ECG trades above typical levels. Peer multiples imply a price about 6% below where it trades (it looks expensive on this basis); the read is fair, priced roughly in line with peer multiples. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 5 valuation methods, at three horizons. Current price $148.83. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $149 ECG trades at 34× p/e, in line with its 34× p/e peer median. Our $143 fair value reflects that, high confidence. Analysts: $115–$180. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 4% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
Only weak execution quality — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Industrials names rated neutral grew net income 57% of the time over the next year (vs 64% for the rest of the cohort, n=4882).
Over the trailing year it converted 1.31x of net income into operating cash flow. Historically, Industrials names rated neutral grew net income 57% of the time over the next year (vs 60% for the rest of the cohort, n=4440).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
Not enough signal yet.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.09 → $1.14 (+4.6% / 30d). 1 raised, 1 cut, 5 covering analysts.
0 upgrades, 0 downgrades / 30d. 50% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$238.
How much price usually moves either way.
On a bad day, this stock has moved -$556.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,026.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Revenue growth is a top priority for Everus. Strong growth signals success in their strategy.
Confirms:Q2 revenue growth exceeds 6% year over year.
Disproves:Q2 revenue growth falls below 3% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ECG yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition and
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$115.00 – $180.00 (median $156.50) · 6 analysts · as of 2026-05-08
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Construction & Engineering.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ECG Everus Construction Group, Inc. | Above typical Show detailsSector percentile: 99 of 100 | full | elevated |
PWR Quanta Services | Typical Show detailsSector percentile: 50 of 100 | expensive | moderate |
FIX Comfort Systems USA | Above typical Show detailsSector percentile: 74 of 100 | expensive | elevated |
EME Emcor | Above typical Show detailsSector percentile: 89 of 100 | full | moderate |
MTZ MasTec | Typical Show detailsSector percentile: 47 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-12.
via XLI
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on increasing revenue growth through strategic initiatives and acquisitions.
Improve operating income through cost management and efficiency improvements.
Aim to increase net income by optimizing operations and strategic growth.
Why it matters: Net income growth is crucial for Everus. It reflects overall business health and success.
Confirms:Net income increases by over 15% compared to Q1.
Disproves:Net income growth is less than 5% compared to Q1.
Why it matters: Better operating income means cost management works well. This helps overall profits.
Confirms:Operating income goes up by more than 10% from Q1.
Disproves:Operating income decreases or grows less than 5% compared to Q1.
Why it matters: The industrial sector is maturing. Changes could impact Everus's growth outlook.
Confirms one read:Sector revenue growth speeds up to over 8% each year.
Confirms the other:Sector revenue growth slows below 4% year over year.